2024
Cost-effectiveness of bevacizumab therapy in the care of patients with hereditary hemorrhagic telangiectasia
Wang D, Ito S, Waldron C, Butt A, Zhang E, Krumholz H, Al-Samkari H, Goshua G. Cost-effectiveness of bevacizumab therapy in the care of patients with hereditary hemorrhagic telangiectasia. Blood Advances 2024, 8: 2835-2845. PMID: 38537061, PMCID: PMC11176968, DOI: 10.1182/bloodadvances.2024012589.Peer-Reviewed Original ResearchIncremental net monetary benefitHereditary hemorrhagic telangiectasiaStandard-of-careBevacizumab therapyWillingness-to-payNet monetary benefitHemorrhagic telangiectasiaWillingness-to-pay thresholdsStandard-of-care strategiesCare of patientsCost-effectiveness analysisAnti-VEGF bevacizumabSystemic antiangiogenic therapyCurrent standard-of-careMonetary benefitsTime horizonFormulary placementHealthcare resource utilizationStandard of careLifetime time horizonPatient quality-of-lifeScenario analysisProbabilistic sensitivity analysesIV bevacizumabAnti-VEGF
2023
Allotransplantation and Gene Therapy Equity for Children with Sickle Cell Disease: Distributional Cost-Effectiveness of Allotransplantation Vs Gene Therapy Vs Standard-of-Care in Pediatric Patients with Sickle Cell Disease in the United States
Goshua G, Ito S, Chetlapalli K, Potnis K, Calhoun C, Krishnamurti L, Krumholz H, Pandya A. Allotransplantation and Gene Therapy Equity for Children with Sickle Cell Disease: Distributional Cost-Effectiveness of Allotransplantation Vs Gene Therapy Vs Standard-of-Care in Pediatric Patients with Sickle Cell Disease in the United States. Blood 2023, 142: 490. DOI: 10.1182/blood-2023-191072.Peer-Reviewed Original ResearchSickle cell diseaseIncremental cost-effectiveness ratioDistributional cost-effectiveness analysisPediatric patientsCell diseaseCost-effectiveness analysisDisease severityHealth resource utilization dataPediatric Health Information SystemGene therapyJustifiable treatment optionTransplant-related mortalityVaso-occlusive crisisExpert clinical experienceMarrow Transplant ResearchSubstantial mortality riskVisual analog scaleQuality-adjusted life expectancyConcomitant riskCost-effectiveness ratioResource utilization dataCost-effectiveness frontierHost diseaseMaximum patientsOpioid therapy
2017
Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial
Arrieta A, Hong JC, Khera R, Virani SS, Krumholz HM, Nasir K. Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial. JAMA Cardiology 2017, 2: 1369-1374. PMID: 29049467, PMCID: PMC5814995, DOI: 10.1001/jamacardio.2017.3655.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnticholesteremic AgentsCardiovascular DiseasesCholesterol, LDLCost-Benefit AnalysisDecision Support TechniquesDrug Therapy, CombinationFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaInsuranceInsurance, HealthInsurance, Health, ReimbursementMaleMarkov ChainsMiddle AgedMyocardial InfarctionPCSK9 InhibitorsQuality-Adjusted Life YearsStrokeUnited StatesConceptsQuality-adjusted life yearsIncremental cost-effectiveness ratioCost-effectiveness ratioProprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitorsCurrent pricesLife yearsPrivate payersAdditional quality-adjusted life yearPreliminary cost-effectiveness analysisCost-effectiveness standardsProbabilistic sensitivity analysesCost-effectiveness analysisPrivate payer perspectiveCost-effectiveness assessmentNegative returnsHealth system perspectiveSignificant discountUS dollarsDrug pricesPatent protectionPricesStatin treatment strategiesHealth insuranceTime horizonSubtilisin/kexin type 9 inhibitorsImplications of Coronary Artery Calcium Testing for Treatment Decisions Among Statin Candidates According to the ACC/AHA Cholesterol Management Guidelines A Cost-Effectiveness Analysis
Hong JC, Blankstein R, Shaw LJ, Padula WV, Arrieta A, Fialkow JA, Blumenthal RS, Blaha MJ, Krumholz HM, Nasir K. Implications of Coronary Artery Calcium Testing for Treatment Decisions Among Statin Candidates According to the ACC/AHA Cholesterol Management Guidelines A Cost-Effectiveness Analysis. JACC Cardiovascular Imaging 2017, 10: 938-952. PMID: 28797417, DOI: 10.1016/j.jcmg.2017.04.014.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAmerican Heart AssociationBayes TheoremClinical Decision-MakingComputer SimulationCoronary AngiographyCoronary Artery DiseaseCoronary VesselsCost-Benefit AnalysisDecision Support TechniquesDrug CostsFemaleGuideline AdherenceHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedModels, EconomicMonte Carlo MethodMultivariate AnalysisPractice Guidelines as TopicPredictive Value of TestsQuality of LifeQuality-Adjusted Life YearsTime FactorsTreatment OutcomeUnited StatesVascular CalcificationConceptsCoronary artery calciumQuality-adjusted life yearsStatin therapyArtery calciumLong-term statin therapyAtherosclerotic cardiovascular disease eventsCholesterol management guidelinesIncremental cost-effectiveness ratioCardiovascular disease eventsAtherosclerotic cardiovascular diseaseCost-effectiveness ratioCost-effectiveness analysisStatin candidatesCholesterol managementCardiovascular diseaseTreatment decisionsAmerican CollegeDisease eventsLifetime horizonLife yearsAmerican HeartSocietal perspectiveManagement guidelinesStatinsPatients
2002
The Cost-Effectiveness of Treatment for Varicocele Related Infertility
PENSON DF, PALTIEL AD, KRUMHOLZ HM, PALTER S. The Cost-Effectiveness of Treatment for Varicocele Related Infertility. Journal Of Urology 2002, 168: 2490-2494. PMID: 12441947, DOI: 10.1016/s0022-5347(05)64175-4.Peer-Reviewed Original ResearchConceptsImmediate IVFHealth care payorsRelated infertilityIntrauterine inseminationTreatment strategiesLive deliveryMain outcome measuresNumber of newbornsAdditional birthsCost-effectiveness analysisInfertile patientsImproved outcomesOutcome measuresPatient's perspectiveSurgical varicocelectomyIVFIncremental costInfertilityPatientsTreatmentPreferred approachBirthPayorsDeliveryVaricocelectomyThe Cost-Effectiveness of Treatment for Varicocele Related Infertility
PENSON D, PALTIEL A, KRUMHOLZ H, PALTER S. The Cost-Effectiveness of Treatment for Varicocele Related Infertility. Journal Of Urology 2002, 168: 2490-2494. DOI: 10.1097/00005392-200212000-00033.Peer-Reviewed Original ResearchImmediate IVFHealth care payorsRelated infertilityIntrauterine inseminationTreatment strategiesLive deliveryMain outcome measuresNumber of newbornsAdditional birthsCost-effectiveness analysisInfertile patientsImproved outcomesOutcome measuresPatient's perspectiveSurgical varicocelectomyAbstract PurposeIVFIncremental costInfertilityPatientsTreatmentPreferred approachBirthPayorsDelivery
1999
Economics, health-related quality of life, and cost-effectiveness methods for the TACTICS (Treat Angina with Aggrastat® [tirofiban] and Determine Cost of Therapy with Invasive or Conservative Strategy)–TIMI 18 trial
Weintraub W, Culler S, Kosinski A, Becker E, Mahoney E, Burnette J, Spertus J, Feeny D, Cohen D, Krumholz H, Ellis S, Demopoulos L, Robertson D, Boccuzzi S, Barr E, Cannon C. Economics, health-related quality of life, and cost-effectiveness methods for the TACTICS (Treat Angina with Aggrastat® [tirofiban] and Determine Cost of Therapy with Invasive or Conservative Strategy)–TIMI 18 trial. The American Journal Of Cardiology 1999, 83: 317-322. PMID: 10072215, DOI: 10.1016/s0002-9149(98)00860-1.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsHealth Utilities IndexLife yearsHealth-related qualityCost-effectiveness methodsNon-Q-wave myocardial infarctionUtility indexCost-effectiveness analysisDetermine CostImpact of invasiveEconomic formsUB92 formulationHealth care costsUnstable anginaRelative value scaleMedicare conversion factorMyocardial infarctionMedicare fee scheduleDepartmental costsEconomicsExpensive formFee scheduleTACTICS-TIMI 18Care costsOutcomes of patientsCost-Effectiveness Analysis and the Treatment of Acute Coronary Syndromes
Krumholz H. Cost-Effectiveness Analysis and the Treatment of Acute Coronary Syndromes. Contemporary Cardiology 1999, 601-610. DOI: 10.1007/978-1-59259-731-4_25.Peer-Reviewed Original ResearchAcute coronary syndromeCoronary heart diseaseHealth care resourcesCost-effectiveness analysisHealth care systemHealth care expendituresCoronary syndromeCardiac eventsPharmacologic interventionsHeart diseaseEfficacious therapyCardiovascular diseaseCare resourcesNew interventionsCare expendituresCare systemHealth benefitsInterventionCare organizationsDiseaseTreatmentStandard practicePatientsHospitalSyndrome